There are 31 papers on fibroblast growth FACTOR-23 in aging research: 3 trials and 19 observational studies in people, 4 in animals, 5 reviews.
4 new papers in 30 daysSee all 62 papers on fibroblast growth FACTOR-23
“the odds ratio for prevalent frailty versus non-frailty per twofold higher FGF23 was 1.34 (95% confidence interval [CI] = 1.01-1.77)”
- Human trial3
- Humans19
- Animals4
Interventions
2SGLT2 inhibitors
upin reviews1
1 study
SGLT2 inhibitors
upin reviews1
SGLT2 inhibitors increase fibroblast growth FACTOR-23 (modest increase).
“a modest increase in phosphate, fibroblast growth factor-23 (FGF-23), and parathyroid hormone (PTH)”
Review
SGLT2 Inhibitors: Dual Effects on Erythropoiesis and Bone Metabolism
Journal of bone metabolism
Pulse-based diet
no changein humans1
1 study
Pulse-based diet
no changein humans1
Pulse-based diet showed no clear effect on fibroblast growth FACTOR-23 in humans.
“However, the circulating FGF23 levels did not change in either group.”
Human trial12 weeksn = 16
Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme
Effects
2Chronic kidney disease progression
no changein humans1
1 study
Chronic kidney disease progression
no changein humans1
Fibroblast growth FACTOR-23 was not clearly linked with chronic kidney disease progression in humans (fully adjusted multivariable models).
“Fully adjusted multivariable models of CKD progression showed no association with FGF23, vitamin D status or PTH.”
Humansfully adjusted multivariable models
BMJ open
Mortality
no changein humans1
1 study
Mortality
no changein humans1
Fibroblast growth FACTOR-23 was not clearly linked with mortality in humans after multivariable adjustment; univariable association was present.
“FGF23 was associated with all-cause mortality in univariable but not multivariable analysis.”
Humansafter multivariable adjustment; univariable association was present
BMJ open
Associations
3Silent brain infarct
upin humans1
1 study
Silent brain infarct
upin humans1
Silent brain infarct is associated with fibroblast growth FACTOR-23 in humans (Atrial fibrillation with low embolic risk).
“Ang-2, FGF-23, and BMP-10 were increased in patients with SBI.”
HumansAtrial fibrillation with low embolic riskn = 70
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
Falls
upin humans1HR 1.99
1 study
Falls
upin humans1HR 1.99
Fibroblast growth FACTOR-23 is linked with a higher risk of falls in humans (HR 1.99 per twofold higher FGF23 (95% CI 1.48-2.68); highest vs lowest quartile HR 2.32 (95% CI 1.26-4.26)).
“the HR per twofold higher FGF23 was 1.99 (95% CI = 1.48-2.68)”
Humansin participants with chronic kidney disease, Cox analysis adjusted for demographics, comorbidities, randomization group, antihypertensives, eGFR, mineral metabolism markers and frailtyper twofold higher FGF23n = 2,376
FGF23, Frailty, and Falls in SPRINT
Journal of the American Geriatrics Society
Frailty
upin humans1OR 1.34
1 study
Frailty
upin humans1OR 1.34
Fibroblast growth FACTOR-23 is associated with frailty in participants with chronic kidney disease, after adjustment (OR 1.34 per twofold higher FGF23 (95% CI 1.01-1.77)).
“the odds ratio for prevalent frailty versus non-frailty per twofold higher FGF23 was 1.34 (95% confidence interval [CI] = 1.01-1.77)”
Humansin participants with chronic kidney disease, after adjustmentper twofold higher FGF23n = 2,376
FGF23, Frailty, and Falls in SPRINT
Journal of the American Geriatrics Society
Funding
1 grant since 2018National Institute on Aging$223K